RxDoctor Payments Data

Ehsan Ghods, DO

Family Medicine · Fairfield, CANPI 1386663508

Payments from drug & device makers

$2,090in general payments, 2019–2025

Across 28 payments — averaging $74.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$701
  • AbbVie$328
  • Lilly USA, LLC$325
  • GSK$310
  • Amgen$122
  • Vertex$103
  • plus $202 from 3 others

What the payments were for

  • Food & beverage$2,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,090 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$250,118
Medicare patients
442
Services billed
3,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide69$147,444
JardianceEmpagliflozin74$114,573
OzempicSemaglutide55$87,869
LinzessLinaclotide35$57,619
EliquisApixaban35$39,404
XareltoRivaroxaban25$38,983
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$27,405
JanumetSitagliptin Phos/Metformin Hcl19$24,390
MyrbetriqMirabegron17$22,560
JanuviaSitagliptin Phosphate11$17,633
VascepaIcosapent Ethyl14$9,703
Breo ElliptaFluticasone/Vilanterol12$9,638
SymbicortBudesonide/Formoterol Fumarate12$7,148
Advair HfaFluticasone Propion/Salmeterol14$6,576
Atorvastatin Calcium713$6,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$701$235,313124 claims
AbbVieLinzess$328$57,61935 claims
Johnson & JohnsonXarelto$85$38,98325 claims
GSKTrelegy Ellipta, Breo Ellipta$310$37,04328 claims
Astellas Pharma US IncMyrbetriq$90$22,56017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Fairfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →